Navigation Links
BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
Date:9/19/2007

ding of the peramivir program, that we may not commence in timely fashion or at all the planned Phase III trial for peramivir and if commenced, it may not be successful, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of Fodosine(TM) in both T-ALL and CTCL may not be successful, that we may not resolve satisfactorily the particulate matter issue with the intravenous formulation of Fodosine(TM), that DHHS could reduce or eliminate funding for peramivir, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future clinical trials may not have positive results, that we may not be able to complete successfully the Phase IIb trials for Fodosine(TM) that are currently planned to be pivotal, that we may not be able to announce preclinical developments for additional compounds by year-end 2007 as currently proposed, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not reach favorable agreements with potential pharmaceutical and biotech partners for further development of its product candidates, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange C
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... 29, 2015 , ... Finding gooey or crusty material in the corner of ... a considerable number of terms in popular use to describe it, ophthalmologists call it ... of mucus, blood cells, skin cells and dust, but until now there has been ...
(Date:7/29/2015)... Bruno, CA. (PRWEB) , ... July 29, 2015 ... ... agreement with PRC Clinical, a Silicon Valley-based CRO specializing in Clinical ... advisory services, and patient recruitment services. The core expertise of PRC Clinical is ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel, a nighttime-specific product that targets ... amount of sugars that are able to enter fat cells, inhibiting the formation ...
(Date:7/29/2015)... ... ... Costello served as Lead Levee Design Engineering Manager for a feasibility study ... from future storm surge flooding, such as occurred in Hurricane Ike in 2008. ... providing protection, Costello also balanced socio-economic and environmental needs and concerns. The ...
Breaking Biology Technology:What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Preventing Storm Surge Flooding in Houston 2
... 1 Environmental Tectonics Corporation,s (OTC Bulletin Board: ETCC) ("ETC" ... of a BARA-MED((R)) XD Monoplace Hyperbaric Chamber to ... area. , , Hyperbaric Oxygen Therapy ... patient breathes 100% oxygen while fully enclosed in a specially ...
... China, Sept. 1 /PRNewswire-Asia-FirstCall/ -- China Kangtai Cactus,Biotech ... grower,developer, manufacturer and marketer of a variety of ... has successfully completed the trial,production of cactus-based cigarettes ... quarter in 2009: (i) low nicotine and (ii) ...
... BOSTON, Sept. 1 PAREXEL International Corporation (Nasdaq: ... Robert Baird 2009 Healthcare Conference in New York, NY. James ... be making a formal presentation on PAREXEL at 10:30 a.m. EDT ... live webcast of this presentation will be available under the "Upcoming ...
Cached Biology Technology:Environmental Tectonics Corporation's BioMedical Systems Division Announces the Sale of a Monoplace Hyperbaric Chamber 2Environmental Tectonics Corporation's BioMedical Systems Division Announces the Sale of a Monoplace Hyperbaric Chamber 3Environmental Tectonics Corporation's BioMedical Systems Division Announces the Sale of a Monoplace Hyperbaric Chamber 4China Kangtai Cactus Biotech to Launch Patented Cactus-based Low Tar, Low or Zero Nicotine Cigarettes 2China Kangtai Cactus Biotech to Launch Patented Cactus-based Low Tar, Low or Zero Nicotine Cigarettes 3PAREXEL International to Present at Robert Baird 2009 Healthcare Conference 2
(Date:7/27/2015)... SAN JOSE, Calif. , July 27, 2015 ... leading developer of human interface solutions, today announced ... ClearPad ® touchscreen solution for its stylish ... controller for its proven reliability, low power and ... with a wet finger. Huawei designers also required ...
(Date:7/27/2015)... , July 27, 2015   Zynx ... and experience-based clinical improvement solutions, today announced that ... is now available on Android smartphones and tablets. ... and post-care organizations can use ZynxCarebook to securely ... patient,s condition, streamline care transitions to other care ...
(Date:7/23/2015)... BEDFORD, Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... services, today reported financial results for its second quarter ended ... quarter of 2015 was $4.5 million, a decrease of 33% ...  Net income in the second quarter of 2015 was $0.3 ... million, or $0.04 per diluted share, in the same period ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... found a way to stabilize hemoglobin, the oxygen carrier ... to the development of stable vaccines and affordable artificial ... the polymer poly(acrylic acid) around hemoglobin, protecting it from ... to maintain its biological function and structural integrity. ...
... from the Photosynthetic Systems Division at the U.S. Department ... at Rensselaer Polytechnic Institute are expanding a successful research ... protein, Photosystem II. The high-impact research, led by professor ... as an abundant source of renewable energy. "I ...
... Dec. 3, 2013 (Toronto) - People who carry a high-risk ... in childhood, decades before the illness appears, new research from ... The gene, called SORL1, is one of a number of ... the most common form of the illness. SORL1 carries the ...
Cached Biology News:New method for stabilizing hemoglobin could lead to stable vaccines, artificial blood 2New method for stabilizing hemoglobin could lead to stable vaccines, artificial blood 3Rensselaer researchers to map step-by-step mechanism of photosynthesis 2Rensselaer researchers to map step-by-step mechanism of photosynthesis 3Rensselaer researchers to map step-by-step mechanism of photosynthesis 4Alzheimer's risk gene may begin to affect brains as early as childhood, CAMH research shows 2Alzheimer's risk gene may begin to affect brains as early as childhood, CAMH research shows 3
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Mus musculus MARCKS-like protein, mRNA...
Tris-Hepes kit of BG-163 & BG-165 (order number BG-166)...
... The NEW HandyStep electronic from BRAND ... pipetting. It is the only electronic, ... standard syringe tips, including BRAND PD-Tip ... Plus, Fisherbrand Dispenser Tips,and VWRbrand Combi-Syringes. ...
Biology Products: